Transthyretin (TTR) L55P Variant Monomers

Human Recombinant Transthyretin (TTR) L55P Variant Monomers

Product Specifications

Background

Transthyretin is a transport protein in the serum and cerebospinal fluid that carried the thyroid hormone Thyroxine and retinol-binding protein bound to retinol. TTR misfolding and aggregation is known to be associated with the amyloiddiseases SSA, FAP and FAC (1-5) . TTR is also thought to have beneficial side effects, such as binding to beta-amyloid protein, preventing beta-amyloid from accumulating into the plaques associated with Alzheimer's Disease (6) . The L55P variant TTR is distinct from the other variants in that the L55P tetramer can dissociate to the monomeric amyloidogenic intermediate and form fibril precursors (7) .

Product Name Alternative

Amyloid polyneuropathy Protein Monomer, Amyloidosis I Protein Monomer, ATTR Protein Monomer, Carpal tunnel syndrome 1 Protein Monomer, CTS Protein Monomer, CTS1 Protein Monomer, = HEL111 Protein Monomer, HsT2651 Protein Monomer, PALB Protein Monomer, Prealbumin Protein Monomer, Prealbumin amyloidosis type I Protein Monomer, Prealbumin Thyroxine-binding Protein Monomer, TBPA Protein Monomer, Thyroxine binding prealbumin Protein Monomer, Transthyretin Protein Monomer, TTHY_HUMAN Protein Monomer, TTR Protein Monomer, TTR protein

UNSPSC

12352202

UN Code

Non-hazardous

Hazard Statement

Non-hazardous

Gene ID

7276

Swiss Prot

P02766

Accession Number

NP_000362.1

Cellular Locus

Cytoplasm | Extracellular exosome | Extracellular Region | Lysosome

Expression System

E. coli

Host

E. coli

Origin Species

Human

Target

Transthyretin (TTR)

Conjugation

No tag

Nature

Recombinant

Sequence

MGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGEPHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE

Applications

WB | SDS-PAGE | In vivo assay | In vitro assay

Field of Research

Purification Method

Ion-exchange Purified

Purification

Ion-exchange Purified

Limit Of Detection

Certified >95% pure using SDS-PAGE analysis.

Concentration

Lot/batch specific. See included datasheet.

Purity

>95%

Weight

0.2

Length

Full length

Buffer

PBS pH 7.4

Molecular Weight

13.876 kDa

Precautions

Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.

Additionnal Information

For corresponding PFFs, see catalog# SPR-464

References & Citations

1. Zeldenrust S.R., Benson M.D. (2010). Wiley. pp. 795–815. 2. Westermark P., Sletten K., Johansson B., Cornwell G.G. (1990). Proc. Natl. Acad. Sci. U.S.A. 87(7): 2843–5. 3. Andrade C. (1952). Brain. 75(3): 408–27. 4. Coelho T. (1996). Curr. Opin. Neurol. 9(5): 355–9. 5. Jacobson D.R, et. al. (1997). N. Engl. J. Med. 336(7): 466–73. 6. Li X. (2011). Mol Neurodegener. 6(1):79. 7. Lashuel H.A., Wurth C., Woo L., and Kelly J.W. (1999) Biochem. 38(41): 13560-13573.

Shipping Conditions

Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order.

Storage Conditions

-80ºC

Notes

For corresponding PFFs, see catalog# SPR-464

Protein Length

Full length

Background Reference 01

1. Zeldenrust S.R., Benson M.D. (2010) . Wiley. pp. 795–815. 2. Westermark P., Sletten K., Johansson B., Cornwell G.G. (1990) . Proc. Natl. Acad. Sci. U.S.A. 87 (7) : 2843–5. 3. Andrade C. (1952) . Brain. 75 (3) : 408–27. 4. Coelho T. (1996) . Curr. Opin. Neurol. 9 (5) : 355–9. 5. Jacobson D.R, et. al. (1997) . N. Engl. J. Med. 336 (7) : 466–73. 6. Li X. (2011) . Mol Neurodegener. 6 (1) :79. 7. Lashuel H.A., Wurth C., Woo L., and Kelly J.W. (1999) Biochem. 38 (41) : 13560-13573.